Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
NCT02104739 on ClinicalTrials.gov · last registry update 2018-07-03
A small phase 4 — 21 participants, against a typical 75. The sponsor logged completion for March 2017. Primary outcome, as filed: Monocyte NfkB Levels as Detected by Western Blotting. exenatide is approved in the US, but not for obesity and prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- The University of Texas Health Science Center, Houston
- Sponsor type
- Other
- Enrollment
- 21
- Started
- 2014-04
- Primary completion
- 2017-03 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Monocyte NfkB Levels as Detected by Western Blotting
Conditions studied
Prediabetes · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.